Algernon Pharmaceuticals Inc.

CCSE:AGNCanadian Securities Exchange

0.40

CAD

+0.01

(+1.27%)

ISIN

CA01559C1068

Return %

Stock

S&P 500

-52.94

14.20

-83.67

81.12

-98.97

68.34

Use logarithmic scale

Stock Prices API ChatGPT

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	2025 Y	TTM
Revenue per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Basic EPS, GAAP	- -	-81.69	-15.43	-6.97	-8.89	-20.3	-10.4	-8.71	-4.48	-0.25	-0.58	-0.9
Free Cash Flow per Basic Share	- -	-18.25	-10.67	-4.58	-8.67	-15.96	-10.69	-4.4	-1.72	-1.39	-0.4	-0.65
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	- -	-0.8	-6.81	-2.68	10.87	9.23	3.1	2.77	-1.74	-0.6	-0.13	0.06
Tangible Book Value per Share	- -	18.89	12.17	9.61	-0.13	17.1	5.3	0.53	-1.53	-0.5	-0.54	-1.08
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	1	1	2	2	3	2
Sales/Revenue/Turnover	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Depreciation Expense	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	- -	-7	-2	-1	-2	-9	-8	-6	-7	-1	-2	-2
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Working Capital	1	2	1	1	- -	7	4	- -	-2	-1	-2	-2
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	1	2	2	1	5	12	9	6	1	2	3	2
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	-275.5	-250.15	-286.12	- -	- -	- -	- -

Capital Structure

CAD

•

in mil. unless spec.

	Aug'25	Nov'26	Feb'26
ST Debt	- -	- -	- -
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	1	1
Shares Outstanding	3	4	5
Market Capitalization	1	2	1

Working Capital

CAD

•

in mil. unless spec.

	Aug'25	Nov'26	Feb'26
Total Current Assets	1	1	1
Cash, Cash Equivalents & STI	- -	- -	- -
Accounts Receivable, Net	- -	- -	- -
Inventories	- -	- -	- -
Total Current Liabilities	2	2	2
Payables & Accruals	2	2	2
ST Debt	- -	- -	- -
Deferred Revenue	- -	- -	- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Total Equity	37.74%	-13.21%	24.28%
Free Cash Flow	- -	-21.68%	-57.69%
Net Income, GAAP	- -	25.93%	241.38%
Sales/Revenue/Turnover	- -	- -	- -
Total Cash Common Dividend	- -	- -	- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year	Q1	Q2	Q3	Q4	FY
2024	- -	- -	- -	- -	- -
2025	- -	- -	- -	- -	- -
2026	- -	- -	- -	- -	- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year	Q1	Q2	Q3	Q4	FY
2024	-0.33	-0.52	0.66	- -	-0.25
2025	-0.14	-1.36	-0.2	- -	-0.58
2026	-0.17	-1.07	- -	- -	- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year	Q1	Q2	Q3	Q4	FY
2024	- -	- -	- -	- -	- -
2025	- -	- -	- -	- -	- -
2026	- -	- -	- -	- -	- -

Company Description

Company Profile API ChatGPT

Address
Similar Companies
Business

Company News

Company News API ChatGPT

proactiveinvestors.com
6 months ago
Algernon Health announces effective date of name change to Grey Health Matters
proactiveinvestors.com
7 months ago
Algernon Health CEO outlines US brain imaging network plans - ICYMI
proactiveinvestors.com
7 months ago
Small Cap Watch: Lindian, Critical Resources, Resokution Minerals and more...
proactiveinvestors.com
7 months ago
Estee Lauder’s potential merger with Puig seen as transformational move

Unlock non-US companies

Already premium?

Algernon Pharmaceuticals Inc.

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Company Description

Company News

Unlock non-US companies

Unlock non-US companies